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IN VITRO KNOCKDOWN OF SOX9 AFFECTS CELL SURVIVAL VIA P21
AND CYCLIN D1 AND FAVORS OSTEOGENIC DIFFERENTIATION OF MSC
S. Stoeckl1,2, A. Bosserhoff3, C. Go¨ttl1,2, J. Grifka2, S. Gra¨ssel1,2. 1Ctr.
for Med. Biotechnology, Regensburg, Germany; 2Orthopaedic Surgery,
Experimental Orthopaedics, Regensburg, Germany; 3Dept. of Pathology,
Regensburg, Germany
Purpose: The transcription factor Sox9 regulates skeletal growth and
cartilage formation in mesenchymal stem cells and osteochondro-
progenitor cells which can differentiate towards chondrocytes or
osteoblasts. Sox9 is absent in hypertrophic chondrocytes where a
misexpression in vivo causes lack of bone marrow, inhibition of cartilage
resorption and failure of vascular invasion in mice. Moreover, there is
evidence that Sox9 is related to more biological processes than only to
osteo-chondrogenesis, for example cell cycle regulation or tumourigenic
development. The aim of our study is to determine the role of Sox9 in
undifferentiated rat mesenchymal stem cells (rMSC) in cell survival and
its impact on osteogenic differentiation capacity.
Methods: Mesenchymal stem cells (rMSC), isolated from bone-marrow
and adipose tissue of 6 week old rats, were transduced with a retroviral
vector containing a Sox9-speciﬁc shRNA or the Sox9 cDNA sequence for
either generating an in vitro gene knockdown or an overexpression of
Sox9. The Sox9 level was determined with quantitative real-time PCR
(qPCR) on mRNA level and with western blotting and luciferase-reporter
assays on protein level. The effects of the altered Sox9 dose on selected
marker genes were investigated by qPCR, ELISA and western blotting.
Proliferation was quantiﬁed with a BrdU – ELISA, cell cycle distribution
was analysed with FACS and apoptotic activity with a caspase 3/7 assay.
For transduced cells, subjected to osteogenic differentiation for up to
21 days, osteogenic marker gene expression was analyzed via qRT-PCR
and osteogenic differentiation status was investigated with alizarin red
staining.
Results: A reproducible Sox9 knockdown between 50% and 90% and
a 10 to 100 fold overexpression of Sox9 was generated in both, bone
marrow (BM) and adipose tissue derived (AD) MSC. Downstream effects
of Sox9 silencing are a signiﬁcant down regulation of Integrin alpha 11,
Mmp13 and Bcl-2 gene expression in BM-MSC, whereas Osteocalcin is
up regulated in BM-MSC and in AD-MSC. Overexpressing Sox9 results
in opposite regulation of gene expression in rBM-MSC. The BrdU assay,
measurement of cell doubling time and cell cycle analysis via FACS
displays a reduction of proliferation after Sox9 knockdown and a
reduced G1 to S-phase transition rate. A caspase 3/7 assay indicates
an increase in apoptotic activity. The protein amount of p21 and Cyclin
D1, analyzed via western blotting, was clearly increased after Sox9
inhibition. Furthermore, osteogenic differentiation studies demonstrate
an upregulation of Runx2, Mmp13, Vegfa and Osteocalcin in Sox9
knockdown cells after 14 days of osteogenesis, whereas Msx2 and Dlx5
expression is diminished.
Conclusions: Based on these studies, we conclude a negative effect
of Sox9 on apoptosis, and a positive effect on cell proliferation and
cell viability. Alterations of Bcl2, p21 and Cyclin D1 protein expression
after Sox9 reduction point to an important role of Sox9 in cell survival
and cell cycle control in MSC. Possibly, Sox9 modulates transcriptional
activation of inhibitors of p21 and Cyclin D1 or induce phosphorylation
through speciﬁc kinases and consequently their degradation. Our ﬁndings
furthermore indicate an acceleration of osteogenic differentiation due to
inhibition of Sox9, mainly during early osteogenesis of MSC. A possible
mechanism for that effect is a direct or indirect interaction of Sox9 with
one of the major transcription (co) factors in early osteogenesis like
Runx2, Msx2 or Dlx3, three key players of Osteocalcin expression, which
all contain at least one potential Sox9 binding site within their promoter
region.
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FIBROBLAST GROWTH FACTORS 18 AND 9 REGULATE CHONDROGENIC
DIFFERENTIATION OF HUMAN MESENCHYMAL STEM CELLS
D. Correa1, E. Rom2, J.F. Welter1, L. Duesler1, A. Yayon2, A.I. Caplan1.
1Case Western Reserve Univ., Cleveland, OH, USA; 2ProCore Ltd., Ness Ziona,
Israel
Purpose: FGF18 is currently in clinical trials for repair of acute cartilage
injury of the knee and in patients with osteoarthritis. Little is known
about the role of FGF9 in cartilage biology. This work, therefore, aims to
elucidate the effect of these two FGF family members at different stages
of the in vitro chondrogenic differentiation program of hMSCs, and the
relationship between them and the known mitogenic/pro-chondrogenic
effects of FGF2.
Methods: Cell proliferation: coverslip-cultured hMSCs were stimulated
for 72h with 10ng/ml rhFGF2, rhFGF18 or rhFGF9, followed by BrdU
immunostaining. Chondrogenic induction: control and FGF2-expanded
cells were cultured in aggregates with (complete chondrogenic medium)
and without (deﬁned medium) TGF-b in the presence of 10ng/ml
rhFGF18 or rhFGF9 and mutant ligands that exclusively signal through
FGFR3 (FGF18v3 and FGF9v1), starting at different times of the
chondroinductive program. qRT-PCR and immunocytochemistry (ICC)
was performed at days 0 (right after expansion) and 3, followed by
histological/biochemical analysis after 3 weeks. Hypertrophy delay: the
aggregate cultures were switched after 2 weeks to a hypertrophy-
inducing medium (TGF-b withdrawal, low Dexamethasone, 1 ng/ml
Triiodothyronine) for 2 additional weeks, along with rhFGF18, rhFGF9,
FGF18v3, FGF9v1, and neutralizing antibodies against FGFR1 and FGFR3.
Histological/biochemical analysis and Alkaline Phosphatase (ALP) activity
assessment as a marker of hypertrophy-induced changes were then
performed.
Results: Cell proliferation: compared with control (24% BrdU-positive
cells), the mitogenic effect of FGF2 was conﬁrmed (46%), while FGF18 had
no effect (29%) and FGF9 a negative one (15%). Chondrogenic induction:
in FGF2-expanded cells Sox9 was upregulated on day 0, suggesting that
the chondrogenic regulatory machinery is activated earlier by FGF2. By
ICC, Sox9 and BrdU expression did not coincide, suggesting that there
are at least two subpopulations which respond differently to FGF2. FGF2
expansion upregulated FGFR2 and FGFR3, while it downregulated FGFR1,
evident after three days in aggregate culture with complete chondrogenic
medium. FGF18, FGF9 and the mutant ligands (in deﬁned medium)
partially replaced TGF-b chondrogenic induction in control-expanded
cells, while they inhibited differentiation of FGF2-expanded cells. This
suggests that FGFR1 (FGF2) and FGFR2/3 (FGF18/9) signaling antagonize
each other, or that these ligands were at “toxic” concentrations, given the
upregulated receptor expression generated by FGF2 expansion. FGF18
had an anabolic effect on top of TGF-b when added early (d0). This
effect was dissipated when it was administered later (d7 and d14). The
effect is mediated by FGFR3, as FGF18v3 recapitulated the same effect.
These ligands also had a negative effect on chondrogenesis of FGF2-
expanded cells, when administered along with TGF-b, regardless of the
time of administration. Hypertrophy delay: FGF18 and FGF9 delay, mainly
through FGFR3 signaling, the appearance of the induced hypertrophy-
related changes in cell size and ALP activity. Additionally, they still exert a
signiﬁcant anabolic effect (FGF9) even under these special pro-terminally
differentiating conditions.
Conclusions: The 3 factors exhibit important effects at all stages of
hMSC chondrogenesis. FGF2 expands them, and shifts the chondrogenic
program earlier, by upregulating Sox9 expression. FGF18/9, signaling
primarily through FGFR3, partially replaces TGF-b, have anabolic
properties, and delay the appearance of changes related to hypertrophic
differentiation. However, they have a negative impact on FGF2-expanded
cells, which requires further research in order to be able to synergize
their individual positive effects. Collectively, these factors could be used
to optimize the pre-implantation culture conditions of hMSCs when used
as part of engineered cartilage grafts.
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GSK-3ALPHA AND GSK-3BETA MODULATE EARLY STAGES OF
CHONDROCYTE DIFFERENTIATION THROUGH PHOSPHORYLATION
OF RELA/NF-KAPPAB P65
S. Itoh, T. Saito, M. Hirata, M. Ushita, T. Ikeda, K. Nakamura, U-i. Chung,
H. Kawaguchi. Sensory & Motor System Med., Univ. of Tokyo, Tokyo, Japan
Purpose: Glycogen synthase kinase-3 (GSK-3) is a serine/threonine
kinase that phosphorylates various substrates to mediate principal
signals in many cells. Here we have examined individual roles of the
two mammalian isoforms, GSK-3a and GSK-3b, in chondrocytes.
Methods: Chondrocyte differentiation was determined by the mRNA
and protein levels of early differentiation markers (Sox9, Col2a1, and
aggrecan) and late differentiation markers (Col10a1, Indian hedgehog,
and Pth1r). In vitro expression patterns were examined in cultures
of mouse chondrogenic ATDC5 cells with the differentiation medium
(insulin, transferrin, and sodium selenite) and primary chondrocytes
isolated from the ribs of mouse embryos. In vivo expression patterns
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were examined using the immunohistocemistry of the mouse limb
cartilage. Cell proliferation was assessed by PCNA staining. For gain-
and loss-of-function analyses, genes or the speciﬁc siRNAs were
overexpressed in ATDC5 cells with stable retroviral transfection or
in primary chondrocytes with adenoviral transfection. Transcriptional
regulation was examined by luciferase assay using ATDC5 and non-
chondrogenic HeLa cells transfected with a reporter construct containing
a promoter fragment of the differentiation marker genes above.
Transactivity of b-catenin was determined by the TOPﬂash system.
Computational predictions were performed using the online resource
NetworKIN for in vivo kinase-substrate relationships, and the GEO
database for expressions in the growth plate cartilage.
Results: Both isoforms were largely unphosphorylated and active in
the early differentiation stages of chondrocytes in cultured ATDC5
cells and in the mouse limb cartilage. Although Gsk3a−/− mice and
Gsk3b+/− mice showed normal skeletal development, their compound
Gsk3a−/−;Gsk3b+/− mice exhibited dwarﬁsm with impairment of early
chondrocyte differentiation without affecting the later differentiation
or proliferation. Gain- and loss-of-function analyses using cultures
of ATDC5 cells and primary chondrocytes from the knockout mice
with overexpression of GSK-3 isoforms and their siRNAs revealed
that GSK-3a and GSK-3b induced early chondrocyte differentiation
with functional redundancy in a cell-autonomous fashion. This was
independent of the canonical Wnt signaling, since the transcriptional
activity of b-catenin was not altered by the Gsk3 genotypes. Instead,
computational predictions followed by SOX9 and COL2A1 promoter assays
identiﬁed RelA (NF-úB p65) as a key phosphorylation target of GSK-3.
Further analyses by mutagenesis in the 12 putative phosphorylation
sites of RelA revealed that the Thr254-phosphorylation was essential for
GSK-3 to induce chondrocyte differentiation. The Cre-mediated deletion
of RelA in the Relaﬂ/ﬂ chondrocyte culture caused suppression of the early
differentiation markers, which was restored by the RelA overexpression,
but not by the Thr254 mutant or the GSK-3 overexpression. Lastly,
we created conditional knockout mice of Rela in undifferentiated limb
mesenchyme (Prx1-Cre;Relaﬂ/ﬂ) and in cartilage (Col2a1-Cre;Relaﬂ/ﬂ), and
conﬁrmed that both mouse models exhibited dwarﬁsm with impairment
of early chondrocyte differentiation, similar to the Gsk3a−/−;Gsk3b+/−
mice.
Conclusions: This study is the ﬁrst to show in vivo evidence of
the functional relationship of GSK-3a and GSK-3b through analysis of
compound knockout mice. Redundant functions of the two isoforms
through phosphorylation of RelA at Thr254 play a crucial role in early
stages of chondrocyte differentiation.
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THE TRANSCRIPTIONAL REGULATION OF MMP13 BY CPG
METHYLATION IN HUMAN CHONDROCYTES: HIF2-ALPHA IS A
POTENTIAL TARGET
K. Hashimoto1, M. Otero1, K. Imagawa2, M.C. de Andre´s2, H.I. Roach2,
R.O. Oreffo2, M.B. Goldring1. 1Hosp. for Special Surgery, New York, NY,
USA; 2Univ. of Southampton, Southampton, United Kingdom
Purpose: In osteoarthritis (OA), articular chondrocytes undergo
phenotypic change and acquire the ability to over-express matrix-
degrading genes. We previously showed that DNA methylation at CpG
sites in the relevant promoters is correlated with the aberrant expression
of several genes, includingMMP13. However, how CpGmethylation status
intervenes to determine the promoter activity of genes such as MMP13
is still not known. The aims of the study were to determine (1) whether
CpG methylation directly affects MMP13 promoter activities, (2) which
CpG sites are responsible for changes in MMP13 promoter responses and
(3) what transcription factors are involved in CpG methylation-related
promoter regulation of MMP13.
Methods: The methylation status of the MMP13 proximal promoter and
the MMP13 gene expression were quantiﬁed in healthy and OA human
primary chondrocytes by pyrosequencing and RT-qPCR, respectively.
Three MMP13 reporter constructs, spanning −372/+14, −214/+14 and
−86/+14 bp of the proximal human MMP13 promoter were generated
by PCR-ampliﬁcation and cloned into a CpG-free luciferase reporter
vector. CpG-mutant constructs were generated by substituting CG to TG
using the wild-type −214/+14 MMP13 construct as template. Luciferase
activities were quantiﬁed for each reporter construct, untreated or
treated with DNA methyltransferase (M.SssI), and transfected in human
immortalized C28/I2 chondrocytes, alone or in co-transfection with
expression vectors encoding HIF1-alpha, HIF2-alpha, ESE1, cFos, cJun,
Runx2, USF1, GATA1 or Sp1. Chromatin immunoprecipitation (ChIP)
assays were performed in C28/I2 cells in co-transfection experiments
utilizing non-methylated or methylated MMP13 constructs, and HIF2-
alpha expression vectors, and analyzed by qPCR utilizing speciﬁc PCR
primers for the transiently transfected MMP13 constructs.
Results: The aberrant MMP13 gene expression in human primary
OA chondrocytes (25-fold higher compared to non-OA chondrocytes)
correlated with increased DNA demethylation of the MMP13 proximal
promoter, with the CpG site at −110 bp showing the greater percentage
of demethylation from the seven CpG sites contained within the −330/−14
bp proximal sequence. Luciferase assays revealed that methylation of the
wild-type MMP13 reporter constructs lead to a signiﬁcant decrease on
their basal activities. Mutation of different proximal CpG sites indicated
that only the mutation at the −110bp-CpG was able to repress the
basal activity of the non-methylated MMP13 promoter. In agreement,
the MMP13 promoter activity was preserved in a mutant construct
in which all the proximal CpG sites except for −110bp were mutated,
and methylation treatment repressed the activity of the same reporter
construct.. Over-expression of different transcription factors indicated
that only the HIF2-alpha-driven MMP13 transactivation was affected by
CpG methylation at −110bp, correlating with the decreased HIF2-alpha
binding to the methylated MMP13 proximal promoter in ChIP assays.
Conclusions: We here show that CpG methylation directly represses
the MMP13 promoter activity in vitro, and that the methylation status
of the −110bp CpG site is critical for the promoter activity, leading to
its decreased basal and HIF2-alpha-driven activity, and reducing the
binding of HIF2-alpha to the proximal promoter. The latter indicates that
HIF2-alpha shows less afﬁnity to its methylated DNA binding site, and
suggests that HIF2-alpha is likely to be a potential target of epigenetic
transcriptional regulation of MMP13.
Fig. 1. CpG methylation alters the HIF2-alpha-driven MMP13 promoter
transactivation. (a) Single CpG mutation. (b) Triple CpG mutation leaving
only one CpG intact (*p< 0.05; **p < 0.01; ***p < 0.001).
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INTERACTION OF HUMAN MESENCHYMAL STROMAL CELLS AND
REGULATORY T-CELLS IN OSTEOARTHRITIS
S. Hagmann, B. Moradi, T. Mu¨ller, T. Dreher, S. Frank, W. Richter,
T. Gotterbarm. Dept. of Orthopedics, Trauma Surgery and Paraplegiology,
Heidelberg Univ. Hosp., Heidelberg, Germany
Purpose: There is an increasing body of evidence that inﬂammatory
T cells from the synovium have a major role in the progression of
osteoarthritis by overproduction of cytokines and growth factors. The
balance between inﬂammatory and regulatory T cells is considered
to play an important role in this process. Mesenchymal stromal cells
have been extensively investigated for their tissue regeneration potential
through the last two decades. More recently, interest has partially focused
on immunogenic properties of MSC, and their abilities to regulate T-cell
and especially regulatory T-cell (Treg) function. However, their role
in regulation of immunity in arthritic diseases, most importantly in
osteoarthritis, remains mostly unknown. The purpose of this study was
to determine the inﬂuence of mesenchymal stromal cells (MSC) from
osteoarthritis (OA) patients on regulation and recruitment of regulatory
T-cells.
Methods: Bone marrow (BM) and synovial membrane (SM) was
harvested from OA patients during total hip arthroplasty (n = 19).
MSC were isolated from BM and SM and cultured in DMEM-LG
until P2. Functional analysis and immunophenotyping conﬁrmed the
presence of typical MSC markers. Mixed lymphocyte cultures enriched
in CD4+CD25+CD127− regulatory T-cells (Treg+MLC) were derived from
whole blood taken from healthy donors. Treg+MLC and MSC were
